Process Validation Lifecycle Audit Readiness
Ensure your process validation programme follows the FDA lifecycle approach from design through continued verification
Overview
What's Inside
Process validation is a foundational requirement of cGMP and one of the most technically demanding areas that FDA investigators evaluate. The 2011 FDA Process Validation Guidance established a three-stage lifecycle approach — Process Design, Process Qualification, and Continued Process Verification — that replaced the legacy "three consecutive batches" paradigm. Investigators now expect documented evidence of process understanding, risk-based PPQ protocols, and ongoing statistical monitoring of commercial production.
This checklist is built from real FDA 483 observation patterns — including absence of continued process verification programmes, use of statistical methods without documented suitability assessment (e.g., control charts applied to non-normal data), inadequate PPQ rationale for batch count selection, failure to trigger revalidation after process changes, and missing linkages between process design knowledge and commercial control strategies. Each section maps observations to specific regulatory requirements and the evidence investigators expect.
It covers eight critical domains: validation governance and master planning, Stage 1 process design and risk assessment, Stage 2 facility/equipment qualification and PPQ execution, Stage 3 CPV programme design and trend analysis, revalidation triggers and lifecycle management, in-process control sampling strategies and microbiological controls, validation personnel training and competency, and validation documentation with data integrity requirements.
Why It Matters
Process validation deficiencies are consistently among the top FDA 483 observations. Lack of adequate process validation — especially for Stage 3 continued process verification — is a primary focus area during manufacturing inspections. The FDA expects statistical rigour in CPV programmes, risk-based PPQ designs, and documented evidence that the validation lifecycle is actively maintained. Sites that still rely on legacy three-batch validation without lifecycle monitoring face significant regulatory risk.
What's Covered
Sections in this checklist
- Validation Master Plan, governance structure, and regulatory alignment (FDA, ICH, EU GMP)
- Stage 1 Process Design — CQAs, CPPs, design space, risk assessments, and control strategy
- Stage 2 Process Qualification — facility/equipment qualification and PPQ protocol execution
- Stage 2 PPQ — batch rationale, enhanced sampling, statistical acceptance criteria, and report approval
- Stage 3 Continued Process Verification — CPV programme design, control charts, and alert limits
- Stage 3 trend analysis, signal detection, and escalation to revalidation
- Revalidation triggers, change-driven reassessment, and validation lifecycle integration
- In-process sampling strategy, microbiological controls, and contamination control strategy
- Validation training, competency assessment, documentation standards, and data integrity
Who It's For
Target roles
Regulatory Basis
21 CFR 211.100, 21 CFR 211.110, 21 CFR 211.113, FDA Process Validation Guidance (2011), ICH Q8, ICH Q9, ICH Q10, EU GMP Annex 15, FDA Compliance Program 7356.002
Download Process Validation Lifecycle Audit Readiness
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Related Checklists
Batch Record Review & Disposition Audit Readiness
Comprehensive 140+ point audit checklist for pharmaceutical batch production record management covering master batch record control, contemporaneous documentation and GDP compliance, in-process controls and yield calculations, Quality Unit production record review, equipment documentation, labeling and reconciliation, training, electronic systems and data integrity, and trending — grounded in real FDA 483 observation patterns under 21 CFR 211.188 and 211.192.
In-Process Controls & Sampling Audit Readiness
Comprehensive 160-point audit checklist for pharmaceutical in-process controls covering CPP identification and control strategy, sampling plan design and statistical rationale, in-process testing methods and acceptance criteria, hold time validation, Quality Unit oversight, and trend analysis — grounded in real FDA 483 observation patterns under 21 CFR 211.110 and 21 CFR 211.100.
Equipment Cleaning Validation Audit Readiness
Comprehensive 140-point audit checklist for pharmaceutical equipment cleaning validation covering HBEL/MACO acceptance limit determination, worst-case equipment and product grouping, cleaning SOP adequacy, swab and rinse sampling strategy, analytical method validation, dirty and clean hold time studies, and lifecycle change control — grounded in real FDA 483 observation patterns under 21 CFR 211.67 and the EMA HBEL Guideline.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
